Gregory George, MD
Adult Medicine · Sharon, PANPI 1417909243
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by GSK at 28.2% of the total.
Across 384 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$872
- Lilly USA, LLC$636
- AbbVie$614
- Novo Nordisk$366
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$307
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,705100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 120 | $1,889 |
| AstraZeneca | 35 | $872 |
| Lilly USA, LLC | 35 | $636 |
| AbbVie | 35 | $614 |
| Novo Nordisk | 19 | $366 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $307 |
| Pfizer | 17 | $282 |
| E.r. Squibb & Sons, L.L.C. | 15 | $234 |
| Merck | 14 | $201 |
| Johnson & Johnson | 10 | $163 |
| Otsuka America Pharmaceutical, Inc. | 9 | $163 |
| Amgen | 9 | $162 |
| Boston Scientific | 1 | $143 |
| Boehringer Ingelheim | 9 | $141 |
| Novartis | 8 | $123 |
| Exact Sciences | 5 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $40 |
| Lundbeck LLC | 1 | $26 |
| Edwards Lifesciences | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Neurelis, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Athena Bioscience, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$250
- WATCHMAN Access System$143
- AIRSUPRA$104
- FARXIGA$104
How this compares
$6,705 in reported general payments places this provider in the 85th percentile of 52 adult medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 368 | $219,786 |
| XareltoRivaroxaban | 167 | $129,935 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $112,443 |
| JardianceEmpagliflozin | 85 | $76,060 |
| FarxigaDapagliflozin Propanediol | 63 | $60,169 |
| OzempicSemaglutide | 51 | $59,862 |
| TrulicityDulaglutide | 58 | $59,831 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $54,821 |
| EntrestoSacubitril/Valsartan | 57 | $53,364 |
| MounjaroTirzepatide | 34 | $40,649 |
| JanuviaSitagliptin Phosphate | 34 | $30,650 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $26,364 |
| TradjentaLinagliptin | 39 | $23,043 |
| LinzessLinaclotide | 30 | $18,184 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 171 | $14,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $282 | $219,786368 claims |
| Johnson & JohnsonXarelto | $163 | $129,935167 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $872 | $124,392135 claims |
| GSKTrelegy Ellipta | $1,889 | $112,443134 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $141 | $106,714138 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $636 | $100,48092 claims |
| Novo NordiskOzempic, Novolog | $366 | $64,88774 claims |
| NovartisEntresto | $123 | $53,36457 claims |
| MerckJanuvia | $201 | $30,65034 claims |
| AbbVieLinzess, Synthroid | $614 | $22,85191 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $163 | $8,27811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 adult medicine providers in Pennsylvania.
Other adult medicine in Sharon
- Peter HonigPhiladelphia$140K
- Mark WatkinsPhiladelphia$54K
- Emily ScaruzziPhiladelphia$16K
- Harvey SpectorPhiladelphia$15K
- Gina SloboginUpper Chichester$15K
- Larry HahnTrevose$8K
- Victoria KorkusPhoenixville$4K
- Jay RobinsonCoalport$3K
- Matthew KulkaLanghorne$2K
- Matthew SophyPort Carbon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.